Dr. Andreadis on the Current State of CAR T-Cell Therapy in Lymphoma

Video

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses chimeric antigen receptor (CAR) T-cell therapy in lymphoma.

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses chimeric antigen receptor (CAR) T-cell therapy in lymphoma.

In 2017, 2 novel CAR T-cell therapies were approved by the FDA for patients. For non-Hodgkin lymphoma, axicabtagene ciloleucel (axi-cel; Yescarta) was approved in October of 2017 for the treatment of adults with relapsed or refractory lymphoma patients. This approval was based off of the single-arm ZUMA-1 study, in which axi-cel demonstrated an objective response rate of 82% and a complete response rate of 54%.

In the lymphoma sphere, these therapies are producing long term responders, says Andreadis, with some patients experiencing responses of more than 6 months.

The goal right now, Andreadis says, is to determine whether these patients can be cured with CAR T-cell therapy. Due to the specificities and toxicities of the treatment, only specialized centers are currently authorized to use this therapy. Andreadis says that this has contributed to an increase in referral patterns to accommodate patients that may be eligible.

Recent Videos
Ben Samelson-Jones, MD, PhD, assistant professor pediatric hematology, Perelman School of Medicine, University of Pennsylvania and Associate Director, Clinical In Vivo Gene Therapy, Children’s Hospital of Philadelphia
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Steven W. Pipe, MD, a professor of pediatric hematology/oncology at CS Mott Children’s Hospital
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
© 2024 MJH Life Sciences

All rights reserved.